Related Experiment Video
Updated: Mar 1, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Melatonin protects against cisplatin-induced ovarian damage in mice via the MT1 receptor and antioxidant activity
Ricássio S Barberino1, Vanúzia G Menezes1, Anita E A S Ribeiro2
1Nucleus of Biotechnology Applied to Ovarian Follicle Development, Federal University of São Francisco Valley - UNIVASF, Petrolina, Brazil.
Abstract:
This study evaluated the receptor- and/or antioxidant stress-mediated mechanisms by which melatonin prevents the ovarian toxicity of cisplatin treatment. The expression of the MT1 receptor in mouse ovaries was investigated by immunohistochemistry. Pretreatment with melatonin (5, 10, or 20 mg/kg body weight, i.p.) before cisplatin (5 mg/kg body weight, i.p.) was administered to mice once daily for 3 days (phase I). The pharmacological modulation via melatonin type 1 and/or 2 receptors was analyzed by administration of receptor antagonists (luzindole: nonselective MT1/MT2 antagonist; 5 mg/kg body weight or 4-phenyl-2-propionamidotetralin: selective MT2 antagonist; 4 mg/kg body weight) once daily for 3 days, 15 min before the treatment with melatonin and cisplatin (phase II). Thereafter, the ovaries were harvested and used for histological (morphology and activation), immunohistochemical (PCNA, activated caspase-3 and bcl-2 expression), terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling, and fluorescence (reactive oxygen species [ROS], glutathione [GSH], and active mitochondria levels) analyses. The expression of the MT1 protein in mouse ovaries was documented. Pretreatment with 20 mg/kg melatonin before cisplatin administration preserved the normal follicular morphology and cell proliferation rate, reduced apoptosis, ROS production, mitochondrial damage and increased GSH expression, as compared to the cisplatin treatment alone. Additionally, administration of the nonselective MT1/MT2 receptor antagonist inhibited the melatonin ovarian protection from the cytotoxic effects of cisplatin. However, administration of a selective MT2 antagonist did not modify the protective effects observed at 20 mg/kg melatonin. In conclusion, pretreatment with 20 mg/kg melatonin effectively protected the ovaries against cisplatin-induced damage. Moreover, the MT1 receptor and melatonin antioxidant effects mediated this cytoprotective activity.
Insights
Melatonin pretreatment protects against cisplatin-induced ovarian toxicity by preserving follicular morphology and reducing apoptosis. This protective effect is mediated by the MT1 receptor and melatonin's antioxidant properties.
Area of Science:
- Reproductive toxicology
- Pharmacology
- Biochemistry
Background:
- Cisplatin is a widely used chemotherapy agent with known ovarian toxicity.
- Melatonin, a hormone with antioxidant and anti-apoptotic properties, may offer protection against cisplatin-induced damage.
- The specific mechanisms, including receptor involvement and antioxidant stress pathways, require further elucidation.
Purpose of the Study:
- To investigate the protective mechanisms of melatonin against cisplatin-induced ovarian toxicity.
- To determine the role of melatonin receptors (MT1 and MT2) in mediating this protection.
- To evaluate the contribution of antioxidant stress pathways to melatonin's ovarian protective effects.
Main Methods:
- Mice were pretreated with varying doses of melatonin before cisplatin administration.
- Pharmacological modulation of melatonin receptors was assessed using selective and non-selective antagonists.
- Ovarian tissues were analyzed for histological changes, apoptosis markers (activated caspase-3, bcl-2), cell proliferation (PCNA), reactive oxygen species (ROS), glutathione (GSH), and mitochondrial activity.
- MT1 receptor expression was confirmed via immunohistochemistry.
Main Results:
- Melatonin pretreatment (20 mg/kg) preserved ovarian follicular morphology and cell proliferation.
- Melatonin significantly reduced cisplatin-induced apoptosis, ROS production, and mitochondrial damage.
- Melatonin increased GSH expression in ovarian tissues.
- A non-selective MT1/MT2 receptor antagonist abolished melatonin's protective effects, while a selective MT2 antagonist did not.
- MT1 receptor protein expression was confirmed in mouse ovaries.
Conclusions:
- Pretreatment with 20 mg/kg melatonin effectively protects ovaries from cisplatin-induced toxicity.
- The protective effects of melatonin are mediated through the MT1 receptor.
- Melatonin's antioxidant properties play a crucial role in its ovarian cytoprotective activity against cisplatin.

